Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 180-184, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-209006
ABSTRACT
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Citas y Horarios
/
Pirroles
/
Carcinoma de Células Renales
/
Diálisis Renal
/
Supervivencia sin Enfermedad
/
Indoles
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS